LEUKOTRIENE AFFECT ON LUPUS ATHEROSCLEROSIS (THE LALA STUDY) A pilot proof of concept observational single-center study of the levels of leukotriene B4 in patients with systemic lupus erythematosus and non-lupus subjects with and without cardiovascula

Brief description of study

The purpose of this study is to obtain blood in order to identify the level of leukotriene B4 (LTB4) and myeloperoxidase (MPO) in patients with and without systemic lupus erythematosus (SLE) and with and without cardiovascular disease. LTB4 is a biological compound involved in inflammation. MPO is an enzyme found in white blood cells and can affect HDL proteins. The research team will examine if these tests associate with risk for cardiovascular disease in patients with and without SLE. In addition, subjects will be given the option to undergo a coronary artery calcium (CAC) score test, a non-invasive computed tomography (CT) scan of the heart. This study would be performed by a CT technologist with the help of a radiologist. This study would allow the study of current cardiovascular disease in relation to the LTB4 and MPO tests.

Clinical Study Identifier: s18-02087
ClinicalTrials.gov Identifier: NCTs18-02087